Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Imricor Medical Systems, Inc. (IMR.AX)
AUD1.67
+0.00 (+0.00%)
AU ASX Healthcare Medical - Specialties
Address
400 Gateway Boulevard 55337
Burnsville, MN, AU
Burnsville, MN, AU
CEO
Steven Wedan
Website
imricor.com
IPO
2019-08-30
ISIN AU0000054942
Description
Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States, Europe, and the Middle East. The company’s products include Vision-MR Ablation Catheter 2.0, a MR-compatible cardiac ablation catheter; Vision-MR Diagnostic Catheter, a MR-compatible diagnostic catheter; NorthStar mapping system, a real-time, high-resolution soft tissue imaging of MRI to guide and visualize procedures with exceptional clarity; and Advantage-MR EP Recorder / Stimulator. It also offers Vision-MR Dispersive Electrode to minimize eddy currents induced on the device’s conductive pads during mr scanning. Imricor Medical Systems, Inc. was incorporated in 2006 and is headquartered in Burnsville, Minnesota.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD1.67
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
304.3K
Beta
0.43
Float Shares
214.16M
Free Float %
85.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.86% | -4.10% | -11.36% | -18.37% | +17.00% | +14.71% | +0.86% | +514.30% | +9.01% | +25.36% | +25.36% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
1.67
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | +1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-1.30
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Specialties: +8.3%-68.5% Q4'25: -76.7% (vs Q4'23)
-
EPS growth Medical - Specialties: +10.1%+33.3% ★ Q4'25: +53.4% (vs Q4'23)
-
FCF margin FCF growth · Medical - Specialties: +51.3%-7,641.0% Q4'25: -10,323.5% (vs Q4'23)
-
EBIT margin Medical - Specialties: +12.6%-7,796.9% Q4'25: -12,237.7% (vs Q4'23)
-
ROIC Medical - Specialties: +6.6%— Q4'25: +1,789.1% (vs Q4'23)
-
Share dilution Medical - Specialties: 0.0%+37.8% Q4'25: +98.4% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×-1.18× Q4'25: -0.59× (vs Q4'23)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 3 EPS Ana. |
Dec 2027 4 Rev. Ana. 3 EPS Ana. |
Dec 2028 4 Rev. Ana. 3 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
702.2K
est: 695.7K (+0.9%)
|
696.3K
est: 899.2K (-22.6%)
|
816.0K
est: 1.91M (-57.2%)
|
615.6K
est: 600.0K (+2.6%)
|
959.4K
est: 3.80M (-74.8%)
|
302.5K
est: 1.31M (-76.9%)
|
3.20M
1.82M – 4.17M
+145.0% YoY
|
10.31M
9.07M – 11.62M
+221.9% YoY
|
29.95M
24.13M – 35.00M
+190.5% YoY
|
35.26M
28.41M – 41.21M
+17.7% YoY
|
99.79M
80.41M – 116.62M
+183.0% YoY
|
| EBITDA |
-11.43M
est: -695.7K (-1,542.7%)
|
-19.57M
est: -39.24M (+50.1%)
|
-16.47M
est: -114.26M (+85.6%)
|
-21.87M
est: -398.44M (+94.5%)
|
-15.55M
est: -1.27B (+98.8%)
|
-22.56M
est: -1.31M (-1,625.0%)
|
-3.20M
-4.17M – -1.82M
-145.0% YoY
|
-10.31M
-11.62M – -9.07M
-221.9% YoY
|
-29.95M
-35.00M – -24.13M
-190.5% YoY
|
-35.26M
-41.21M – -28.41M
-17.7% YoY
|
-99.79M
-116.62M – -80.41M
-183.0% YoY
|
| EBIT |
-11.96M
est: -695.7K (-1,618.6%)
|
-20.26M
est: -35.39M (+42.8%)
|
-17.18M
est: -103.05M (+83.3%)
|
-22.58M
est: -359.34M (+93.7%)
|
-16.30M
est: -1.15B (+98.6%)
|
-23.59M
est: -1.31M (-1,703.7%)
|
-3.20M
-4.17M – -1.82M
-145.0% YoY
|
-10.31M
-11.62M – -9.07M
-221.9% YoY
|
-29.95M
-35.00M – -24.13M
-190.5% YoY
|
-35.26M
-41.21M – -28.41M
-17.7% YoY
|
-99.79M
-116.62M – -80.41M
-183.0% YoY
|
| Net Income |
-13.08M
est: -24.15M (+45.8%)
|
-20.56M
est: -37.70M (+45.5%)
|
-17.53M
est: -11.16M (-57.2%)
|
-22.63M
est: -12.25M (-84.6%)
|
-29.69M
est: -23.50M (-26.4%)
|
-26.20M
est: -24.17M (-8.4%)
|
-18.14M
-34.61M – -13.20M
+25.0% YoY
|
-15.28M
-26.50M – -9.13M
+15.8% YoY
|
-9.03M
-25.11M – 6.79M
+40.9% YoY
|
—
— – —
+100.0% YoY
|
—
— – —
|
| SGA |
6.01M
est: 7.07M (-14.9%)
|
8.69M
est: 9.13M (-4.9%)
|
7.79M
est: 19.35M (-59.8%)
|
7.82M
est: 6.09M (+28.3%)
|
7.19M
est: 57.08M (-87.4%)
|
9.94M
est: 19.63M (-49.4%)
|
48.09M
27.34M – 62.67M
+145.0% YoY
|
154.81M
136.15M – 174.45M
+221.9% YoY
|
449.68M
362.32M – 525.53M
+190.5% YoY
|
529.37M
426.53M – 618.66M
+17.7% YoY
|
1.50B
1.21B – 1.75B
+183.0% YoY
|
| EPS |
-0.11
est: -0.11 (-2.0%)
|
-0.15
est: -0.15 (-1.3%)
|
-0.12
est: -0.11 (-10.3%)
|
-0.14
est: -0.08 (-70.1%)
|
-0.13
est: -0.07 (-80.5%)
|
-0.09
est: -0.08 (-3.2%)
|
-0.07
-0.11 – -0.04
+16.3% YoY
|
-0.06
-0.09 – -0.03
+13.4% YoY
|
-0.04
-0.08 – 0.02
+40.3% YoY
|
—
— – —
+100.0% YoY
|
—
— – —
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-31.75M
OE per share TTM
-0.12
Owner's Yield
-5.62%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
459.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-3.0K
Shares Outstanding
249.51M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Steve Wedan | President, Chief Executive Officer & Executive Chairman | 878.1K | male |
| Jonathon Gut | Chief Financial Officer & Vice President of Finance | 476.6K | male |
| Greg Englehardt | Vice President of Global Sales | — | male |
| Nick Twohy | Vice President of Marketing & Business Development | — | male |
| Vic Fabano | Vice President of Operations | — | male |
| Zheng Li | Company Secretary | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IMR.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
